Robot-assisted radical prostatectomy has lower biochemical recurrence than laparoscopic radical prostatectomy: Systematic review and meta-analysis

Seon Heui Lee¹, Hyun Ju Seo², Na Rae Lee³, Soo Kyung Son⁴, Dae Keun Kim⁴,⁵, Koon Ho Rha⁶

¹Department of Nursing Science, Gachon University College of Nursing, Incheon, ²Department of Nursing, Chosun University College of Medicine, Gwangju, ³Department of Health Technology Assessment, National Evidence-Based Healthcare Collaborating Agency, Seoul, ⁴Department of Urology, CHA Seoul Station Medical Center, CHA University, CHA Medical School, Seoul, ⁵Department of Urology, Hanyang University School of Medicine, Graduate School, Seoul, ⁶Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea

Purpose: To assess the effectiveness and safety of robot-assisted radical prostatectomy (RARP) versus laparoscopic radical prostatectomy (LRP) in the treatment of prostate cancer.

Materials and Methods: Existing systematic reviews were updated to investigate the effectiveness and safety of RARP. Electronic databases, including Ovid MEDLINE, Ovid Embase, the Cochrane Library, KoreaMed, Kmbase, and others, were searched through July 2014. The quality of the selected systematic reviews was assessed by using the revised assessment of multiple systematic reviews (R-Amstar) and the Cochrane Risk of Bias tool. Meta-analysis was performed by using Revman 5.2 (Cochrane Community) and Comprehensive Meta-Analysis 2.0 (CMA; Biostat). Cochrane Q and I² statistics were used to assess heterogeneity.

Results: Two systematic reviews and 16 additional studies were selected from a search performed of existing systematic reviews. These included 2 randomized controlled clinical trials and 28 nonrandomized comparative studies. The risk of complications, such as injury to organs by the Clavien-Dindo classification, was lower with RARP than with LRP (relative risk [RR], 0.44; 95% confidence interval [CI], 1.23–0.85; p=0.01). The risk of urinary incontinence was lower (RR, 0.43; 95% CI, 0.31–0.60; p<0.000001) and the potency rate was significantly higher with RARP than with LRP (RR, 1.38; 95% CI, 1.11–1.70; I²=78%; p=0.003). Regarding positive surgical margins, no significant difference in risk between the 2 groups was observed; however, the biochemical recurrence rate was lower after RARP than after LRP (RR, 0.59; 95% CI, 0.48–0.73; I²=21%; p<0.00001).

Conclusions: RARP appears to be a safe and effective technique compared with LRP with a lower complication rate, better potency, a higher continence rate, and a decreased rate of biochemical recurrence.

Keywords: Laparoscopy; Meta-analysis; Prostatic neoplasms; Prostatectomy; Robotics

INTRODUCTION

Radical prostatectomy has historically been the preferred treatment option for patients with localized prostate cancer. However, surgical innovations to reduce blood loss and hasten the recovery rate have led to the introduction of...
Robot and laparoscopic radical prostatectomy (LRP) followed by robot-assisted radical prostatectomy (RARP) as alternatives to open surgery [1,2]. RARP was introduced to decrease the difficulty in performing complex laparoscopic procedures such as urethral anastomosis. The robotic platform provided several advantages over LRP, such as seven degrees of freedom, tremor filtration, a three-dimensional magnified view, and preferred ergonomics [3]. Therefore, robot-assisted surgery has become popular in Korea, the United States, and Europe [1,4]. However, this trend has occurred despite a lack of high-quality evidence supporting improvement in outcomes.

Randomized controlled trials comparing the safety and effectiveness of RARP and LRP are limited. Therefore, high-level evidence is a requisite for clinicians needing recent evidence on the treatment of prostate cancer. The primary objective of this study was to determine whether RARP is more effective than LRP in the treatment of prostate cancer in terms of functional, oncological, and perioperative outcomes.

**MATERIALS AND METHODS**

1. **Inclusion criteria**

   Eligible studies included randomized controlled trials and prospective and retrospective cohort studies comparing RARP and LRP. A study was excluded if it did not report any outcomes of interest or functional and oncological outcomes.

2. **Search strategy**

   We searched electronic databases for reviews published through July 2014, including Ovid MEDLINE (Ovid, New York, NY, USA), Ovid EMBASE (Ovid), the Cochrane Library (London, United Kingdom), KoreaMed (KAMJE, Seoul, Korea), Kmbase (MedRIC, Chungbuk, Korea), KISS (Korean Studies Information Co, Paju, Korea), RISS (KERIS, Daegu, Korea), and KisTi (KISTI, Daejeon, Korea). Patient-related search terms (prostatic neoplasm, prostatic cancer, prostatic carcinoma, prostatic tumor), and intervention-related search terms (robotics, computer-assisted surgery, telerobot, remote operation, remote surgery, da Vinci) were combined.

3. **Data synthesis and analysis**

   Two independent reviewers selected the studies, extracted data, and performed quality assessments. The authors assessed the relevance and quality of the selected systematic reviews related to the research question through the revised assessment of multiple systematic reviews (R-Amstar). For the prospective randomized controlled clinical studies, the Cochrane Collaboration’s tool for assessing risk of bias was used to perform the quality evaluations. For the nonrandomized studies on the final selected literature, a revised risk of bias was used to perform the quality

---

**Fig. 1.** Flow diagram of the study selection process.
evaluations. Functional and oncologic outcomes, as well as postoperative complications and perioperative results (operation duration, length of stay), were calculated and compared between the groups.

4. Statistical analysis
Meta-analysis was conducted by using RevMan 5.2 (Cochrane Community, London, United Kingdom) and Comprehensive Meta-Analysis 2.0 (CMA; Biostat, Englewood, NJ, USA). The Cochrane Q and I² statistics were used to assess statistical heterogeneity. The results were expressed as weighted means and standardized mean differences (CIs) for dichotomous variables. For dichotomous variables, the random effect model of Mantel-Haenszel was used, and for continuous data, the random effect model of the inverse-variance method was used. Publication bias was tested by using a funnel plot and Egger’s test. The statistical analyses were reviewed by a statistician with previous meta-analysis experience.

5. Details of included studies
The studies selected are outlined in Fig. 1. Thirty articles were evaluated. There were 2 randomized controlled clinical trials (RCTs) and 28 nonrandomized comparative studies (Table 1).

6. Quality assessment
For the RCTs, there was a low risk of bias in sequence generation, blinding, selective report, and other biases. However, the allocation of concealment was uncertain, and incomplete outcome data were at a high risk of bias. In the cohort studies, sequence generation and allocation of concealment, which are important factors in the quality assessment of therapeutic publications, were at a high risk of bias.

RESULTS

1. Postoperative complications
The risk of complications, such as bladder neck contracture (RR, 0.40; 95% CI, 0.17–0.92; p=0.03), organ injury (RR, 0.23; 95% CI, 0.11–0.49; p=0.0002), and other major complications (Clavien-Dindo III–V) according to the Clavien-Dindo classification (RR, 0.44; 95% CI, 0.23–0.85; p=0.01), was lower for RARP than for LRP. Anastomosis site leakage (RR, 0.67; 95% CI, 0.42–1.08; p=0.10) and the rates of infection (RR, 1.21; 95% CI, 0.84–1.76; p=0.31), ileus (RR, 0.73; 95% CI, 0.38–1.40; p=0.34), and pulmonary embolism (RR, 1.20; 95% CI, 0.22–6.51; p=0.83) were not significantly different between the groups (Fig. 2). No significant difference in the conversion rate (RR, 0.70; 95% CI, 0.25–1.96; p=0.50) was observed. RARP carried a lower risk of transfusion than LRP (RR, 0.70; 95% CI, 0.54–0.91; I²=44%; p=0.007).

2. Perioperative data
The operation time for RARP was shorter than that for LRP (RR, -18.74; 95% CI, -32.15 to -5.33; p=0.006), but the statistical heterogeneity was high (χ²=527.29, df=22, p<0.00001, I²=96%). The hospital stay following RARP was 1.53 days shorter than that following LRP. The results of the subgroup analysis according to region showed a mean difference of -1.13 (95% CI, 2.93–0.67; p=0.22) in the Asia Pacific region, -0.56 (95% CI, 1.14–0.02; p=0.06) in the United States, and 0.32 (95% CI, 0.88–0.25; p=0.28) in Europe. However, the overall statistical heterogeneity was high (I²=94%).

3. Functional outcomes
The functional outcomes were improved in a comparison between RARP and LRP (Fig. 3). The urinary incontinence rate at 12 months was lower for RARP than for LRP (RR, 0.43; 95% CI, 0.31–0.60; p<0.000001), and statistical heterogeneity was low (I²=0%). The potency recovery rate was higher for RARP than for LRP at postoperative 12 months (RR, 1.38; 95% CI, 1.11–1.70; I²=78%; p=0.003). Potency recovery was defined as an International Index of Erectile Function 5 (IIEF-5)>17.

4. Oncologic outcomes
The overall positive surgical margin (PSM) results were investigated in 7 studies. When analyzing PSM rates in the pT2 group, the RARP and LRP series had PSM rates of 14.2% (123 of 864 cases) and 11.3% (97 of 860 cases) with an RR of 1.22 (95% CI, 0.98–1.54; p=0.11). In the pT3 group, the PSM rates for RARP and LRP were 43.1% (116 of 269 cases) and 34.4% (72 of 209 cases) with an RR of 1.26 (95% CI, 1.00–1.58; p=0.05) (Fig. 4). The biochemical recurrence (BCR) rate was significantly lower for RARP than for LRP (RR, 0.59; 95% CI, 0.48–0.73; I²=0%; p<0.00001) (Fig. 4). Five studies used prostate-specific antigen (PSA)≥0.2 ng/mL to indicate BCR, 1 study used PSA≥0.4 ng/mL, and 2 studies did not define the cutoff used. The follow-up period ranged from 3 months to 60 months. The overall BCR rates for RARP and LRP were 8.6% (162 of 1,885 cases) and 13.7% (314 of 2,288 cases).
Table 1. The characteristics of the included studies

| Study            | Study design               | Country  | Sample size | Participants (mean/median age years) | Intervention (surgical technique) | Follow-up (mo) |
|------------------|----------------------------|----------|-------------|--------------------------------------|-----------------------------------|----------------|
| Asimakopoulos    | RCT                        | Italy    | 112         | 61.1±5.1, 7.37 (1.5–9.15) cT1: 25, cT2: 35 | Transperitoneal, antegrade nerve-sparing intrafascial technique | 12             |
| Durand 2008      | Retrospective cohort study | France   | 57          | 59.6±5.4, 8.9 (5.8–9.2) cT1: 14, cT2: 38 | Transperitoneal approach           | 12             |
| Hakimi 2009      | Prospective cohort study   | USA      | 150         | 59.6 (43–72) 7.5 pT2: 71, pT3: 4 | Nerve-sparing technique            | 12             |
| Ball 2006        | Prospective cohort study   | USA      | 206         | 61±7, 7.2±7.1 cT1: 100, cT2: 24, cT3: 0 | Bladder neck preservation          | 36             |
| Bolenz 2010      | Retrospective cohort study | USA      | 473         | 59.5±4.1, 5.4 (4.1–6.5) pT2: 11, pT3: 11 | Transperitoneal approach           | 12             |
| Drouin 2009      | Retrospective cohort study | France   | 156         | 61.8 (39–73) 7.9 (3.4–37) cT1: 55, cT2: 30 | Transperitoneal approach           | 48.4           |
| Gosseine 2009    | Prospective cohort study   | France   | 247         | 63.7 (40–83) cT2: 77, cT3: 1 | Transperitoneal approach of Montsouris technique | >0.05          |
| Hu 2006          | Retrospective cohort study | USA      | 680         | 62.1 (41–84) cT1: 269, cT2: 86, cT3: 3 | Transperitoneal approach of Montsouris technique | 5.3            |
| Joseph 2005      | Retrospective cohort study | France/USA| 100        | 59.6±1.6, 7.3±1.26 pT2: 44, pT3: 6 | Extraperitoneal approach            | >0.05          |
| Rozet 2007       | Retrospective cohort study | France   | 266         | 62.5 (47–74) 7.8 (3.2–19) cT1: 91, cT2: 41, cT3: 1 | Extraperitoneal approach           | 5.3            |
| Trabulsi 2008    | Retrospective cohort study | USA      | 240         | 66.3 (50–77) 9.98 (2.91–26.3) cT1: 51, cT2: 9 | Transperitoneal approach           | 16.8           |
| Cho 2009         | Retrospective cohort study | South Korea| 120       | 66.5 (57–75) 11.04 (2.72–36.6) cT1: 51, cT2: 3 | Transperitoneal approach of Montsouris technique | 51.2           |
| Kasraeian 2011   | Retrospective cohort study | France   | 400         | 61.9 (45–75) 6.8 (2.7–48.8) cT1: 131, cT2: 68 | Extraperitoneal interfascial technique | 16.8           |
| Kermanec 2010    | Retrospective cohort study | France   | 397         | 61.84, 7.86, 7.86 | Extraperitoneal interfascial technique | 16.8           |
| Study                  | Study design            | Country      | Sample size | Participants (mean/median age years mean/median PSA ng/mL, clinical/pathologic T stage) | Intervention (surgical technique) | Follow-up (mo) |
|-----------------------|-------------------------|--------------|-------------|---------------------------------------------------------------------------------|-----------------------------------|----------------|
| Kermarrec 2010 [35]   | Retrospective cohort study | France       | 397         | Total: 60.6; RARP: 61.84, LRP: 7.86; cT1: 129, cT2: 92, cT1: 104, cT2: 72 | Transperitoneal Montsouris technique | 0.16            |
| Koutridis 2012 [36]   | Prospective cohort study | France       | 410         | Total: 60.9; RARP: 61.9, LRP: 7.5; cT1: 3, cT2: 102, cT2: 74 | Transperitoneal Montsouris technique | 0.08            |
| Lee 2009 [37]         | Retrospective cohort study | South Korea  | 52          | Total: 64.6; RARP: 62, LRP: 8.1; cT1: 5, cT2: 12; cT2: 7 | Transperitoneal approach | 0.612           |
| Magheli 2011 [38]     | Retrospective cohort study | USA          | 1,044       | Total: 58.3; RARP: 58, LRP: 7.4; cT1: 1, cT2: 105 | Transperitoneal approach | 0.080           |
| Nakamura 2011 [39]    | Retrospective cohort study | USA          | 10          | Total: 65; RARP: 64, LRP: 5; cT1: 59–73, cT2: 7–12; cT2: 7–12 | Transperitoneal approach | 0.852           |
| Park 2013 [40]        | Retrospective cohort study | South Korea  | 327         | Total: 63; RARP: 67, LRP: 4.9; cT1: 49, cT2: 105, cT3: 50 | Transperitoneal approach | <0.001          |
| Ploussard 2014 [41]   | Prospective cohort study | France       | 2,386       | Total: 62.7; RARP: 62, LRP: 9.2; cT1: 81.8% | Transperitoneal approach | 1.00            |
| Poppiglia 2013 [18]   | RCT                     | Italy        | 120         | Total: 63.9; RARP: 64, LRP: 6.8; cT1: 4 | Transperitoneal antegrade approach | 0.959           |
| Berge 2013 [1]        | Prospective cohort study | USA          | 420         | Total: 61.7; RARP: 62, LRP: 9.2; cT1: 104–70, cT2: 60 | Transperitoneal approach | 0.9             |
| Stolzenburg 2013 [42] | Prospective cohort study | Germany      | 200         | Total: 61.2; RARP: 63, LRP: 8.8; cT1: 7 | Transperitoneal approach | 0.1             |
| Willis 2012 [43]      | Prospective cohort study | USA          | 282         | Total: 58.1; RARP: 58, LRP: 6.2; cT1: 2 | Transperitoneal approach | 0.86            |
| Wolanski 2012 [44]    | Retrospective cohort study | Australia    | 160         | Total: 61.4; RARP: 61, LRP: 6.0; cT1: 19, cT2: 22 | Transperitoneal approach | 0.921           |

PSA, prostate-specific antigen; RARP, robot-assisted radical prostatectomy; LRP, laparoscopic radical prostatectomy; RCT, randomized controlled clinical trial.
A Clavien-dindo classification

| Study or subgroup | RARP | LRP | Risk ratio | Risk ratio |
|-------------------|------|-----|------------|------------|
|                    | Events | Total | Events | Total | Weight (%) | M-H, random, 95% CI | Year | M-H, random, 95% CI |
| **1.9.1 Minor complications** | | | | | | | | |
| Menon 2002         | 1     | 40  | 2      | 40  | 3.3         | 0.50 [0.05, 5.30]   | 2002 |
| Sundaram 2004      | 1     | 10  | 1      | 10  | 2.9         | 1.00 [0.07, 13.87]  | 2004 |
| Hu 2006            | 62    | 322 | 102    | 358 | 9.8         | 0.68 [0.51, 0.89]   | 2006 |
| Joseph 2007        | 34    | 754 | 195    | 800 | 9.6         | 0.18 [0.13, 0.26]   | 2007 |
| Rozet 2007         | 33    | 133 | 14     | 133 | 9.0         | 2.36 [1.32, 4.20]   | 2007 |
| Drouin 2009        | 10    | 71  | 5      | 85  | 7.3         | 2.39 [0.86, 6.68]   | 2009 |
| Gosseine 2009      | 4     | 122 | 8      | 125 | 6.7         | 0.51 [0.16, 1.66]   | 2007 |
| Bolenz 2010        | 12    | 262 | 4      | 211 | 6.9         | 2.42 [0.79, 7.38]   | 2010 |
| Philippe 2012      | 8     | 73  | 18     | 87  | 8.3         | 0.53 [0.24, 1.15]   | 2012 |
| Ploussard 2014     | 43    | 1,009 | 51  | 1,377 | 9.5 | 1.15 [0.77, 1.71] | 2014 |
| **Subtotal (95% CI)** | 2,796 | 3,226 | 73.1 | 0.87 [0.46, 1.64] |

Total events 208
Heterogeneity: $\chi^2 = 0.79, \; \mathrm{df} = 9 \; (p < 0.0001); \; I^2 = 90\%$
Test for overall effect: $Z = 0.44 \; (p = 0.66)$

**1.9.2 Major complications**

| Study or subgroup | RARP | LRP | Risk ratio | Risk ratio |
|-------------------|------|-----|------------|------------|
|                    | Events | Total | Events | Total | Weight (%) | M-H, fixed, 95% CI | Year | M-H, fixed, 95% CI |
| Menon 2002         | 0     | 40  | 2      | 40  | 2.3         | 0.20 [0.01, 4.04]   | 2002 |
| Hu 2006            | 6     | 322 | 30     | 358 | 7.9         | 0.22 [0.09, 0.53]   | 2006 |
| Rozet 2007         | 1     | 133 | 1      | 133 | 2.7         | 1.00 [0.06, 15.82]  | 2007 |
| Drouin 2009        | 0     | 71  | 1      | 85  | 2.1         | 0.40 [0.02, 9.62]   | 2009 |
| Philippe 2012      | 4     | 73  | 7      | 87  | 6.6         | 0.68 [0.21, 2.24]   | 2012 |
| Ploussard 2014     | 3     | 1,009 | 3  | 1,377 | 5.2 | 1.36 [0.28, 6.75] |
| **Subtotal (95% CI)** | 1,648 | 2,080 | 26.9 | 0.44 [0.23, 0.85] |

Total events 14
Heterogeneity: $\chi^2 = 0.27, \; \mathrm{df} = 5 \; (p = 0.36); \; I^2 = 9\%$
Test for overall effect: $Z = 2.43 \; (p = 0.01)$

Total (95% CI) 4,444 5,306 100.0 0.75 [0.44, 1.26]

Total events 222
Heterogeneity: $\chi^2 = 0.72, \; \mathrm{df} = 15 \; (p < 0.0001); \; I^2 = 85\%$
Test for overall effect: $Z = 1.09 \; (p = 0.28)$

Test for subaroup differences: $\chi^2 = 2.09, \; \mathrm{df} = 1 \; (p = 0.15); \; I^2 = 52.2\%$

B Organ injury

| Study or subgroup | RARP | LRP | Risk ratio | Risk ratio |
|-------------------|------|-----|------------|------------|
|                    | Events | Total | Events | Total | Weight (%) | M-H, fixed, 95% CI | Year | M-H, fixed, 95% CI |
| Hu 2006            | 3     | 322 | 23     | 358 | 60.2        | 0.15 [0.04, 0.48]   | 2006 |
| Lee 2009           | 0     | 21  | 1      | 31  | 3.4         | 0.48 [0.02, 11.36]  | 2009 |
| Cho 2009           | 0     | 60  | 2      | 60  | 6.9         | 0.20 [0.01, 4.08]   | 2009 |
| Drouin 2009        | 0     | 71  | 1      | 85  | 3.8         | 0.40 [0.02, 9.62]   | 2009 |
| Stolzenburg 2013   | 0     | 100 | 0      | 100 | Not estimable | 2013 |
| Ploussard 2014     | 3     | 1,009 | 11  | 1,377 | 25.7 | 0.37 [0.10, 1.33] |
| **Total (95% CI)** | 1,583 | 2,011 | 100.0 | 0.23 [0.11, 0.49] |

Total events 6
Heterogeneity: $\chi^2 = 1.46, \; \mathrm{df} = 4 \; (p = 0.83); \; I^2 = 0\%$
Test for overall effect: $Z = 3.77 \; (p = 0.0002)$

Fig. 2. Cumulative analyses of robot-assisted radical prostatectomy comparing laparoscopic radical prostatectomy in postoperative complication (A: Clavien-dindo classification, B: Organ injury). RARP, robot-assisted radical prostatectomy; LRP, laparoscopic radical prostatectomy; M-H, Mantel Haenszel; CI, confidence interval; df, degrees of freedom.

5. Publication bias

A funnel plot analysis for organ injury, blood transfusion rate, length of stay, potency, and overall BCR revealed a symmetrical funnel plot, indicating no publication bias (Fig. 5) ($p = 0.53, \; p = 0.47, \; p = 0.26, \; p = 0.10, \; \text{and} \; p = 0.70$, respectively, Egger test). However, operative time revealed asymmetry on the funnel plot ($p = 0.01$, Egger test).

DISCUSSION

Our study revealed three important findings: (1) the risk of complications after RARP was significantly lower than
A. Urinary incontinence rate

| Study or subgroup | RARP | LRP | Weight (%) | Risk ratio M-H, fixed, 95% CI | Year |
|-------------------|------|-----|------------|-------------------------------|------|
| Trabulsi 2008     | 12   | 205 | 13.2       | 0.33 [0.14, 0.76]             | 2008 |
| Cho 2009          | 4    | 60  | 17.0       | 0.24 [0.08, 0.66]             | 2009 |
| Hakimi 2009       | 5    | 75  | 8.0        | 0.63 [0.21, 1.82]             | 2009 |
| Asimakopoulos 2011| 3    | 52  | 9.3        | 0.35 [0.10, 1.19]             | 2011 |
| Park 2013         | 23   | 183 | 35.9       | 0.57 [0.35, 0.92]             | 2013 |
| Porpiglia 2013    | 6    | 50  | 16.6       | 0.37 [0.16, 0.87]             | 2013 |
| **Total (95% CI)**| 625  | 437 | 100.0      | 0.43 [0.31, 0.60]             |      |

Test for overall effect: Z=5.09 (p<0.00001)
Heterogeneity: Chi^2=3.61, df=5 (p=0.61); I^2=0%

B. Sexual function recovery rate

| Study or subgroup | RARP | LRP | Weight (%) | Risk ratio M-H, random, 95% CI | Year |
|-------------------|------|-----|------------|-------------------------------|------|
| Hakimi 2009       | 43   | 58  | 14.6       | 1.13 [0.89, 1.45]             | 2009 |
| Cho 2009          | 16   | 53  | 7.2        | 0.95 [0.52, 1.75]             | 2009 |
| Asimakopoulos 2011| 40   | 62  | 10.6       | 2.04 [1.35, 3.09]             | 2011 |
| Willis 2012       | 21   | 24  | 14.7       | 1.31 [1.03, 1.66]             | 2011 |
| Park 2013         | 64   | 183 | 11.9       | 1.53 [1.07, 2.18]             | 2013 |
| Berge 2013        | 24   | 58  | 11.3       | 0.88 [0.60, 1.30]             | 2013 |
| Porpiglia 2013    | 28   | 35  | 12.2       | 1.47 [1.04, 2.08]             | 2013 |
| Ploussard 2014    | 582  | 1,009| 17.5      | 1.83 [1.66, 2.01]             | 2014 |
| **Total (95% CI)**| 1,482| 1,850| 100.0     | 1.38 [1.11, 1.70]             |      |

Test for overall effect: Z=2.97 (p=0.003)
Heterogeneity: Tau^2=0.06; Chi^2=32.16, df=7 (p=0.00001); I^2=78%

Fig. 3. Cumulative analyses of robot-assisted radical prostatectomy comparing laparoscopic radical prostatectomy in functional outcome (A: Urinary incontinence rate; B: Sexual function recovery rate). RARP, robot-assisted radical prostatectomy; LRP, laparoscopic radical prostatectomy; M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom.

after LRP; (2) in comparison with LRP, the risk of urinary incontinence at 12 months was significantly lower and the potency rate was higher with RARP; (3) the BCR rate was significantly lower after RARP than after LRP.

The major findings of this meta-analysis showed significant differences in complications such as organ injury and other major complications according to the Clavien-Dindo (III–V) classification. The major complication rate was significantly lower for RARP than for LRP. Although both laparoscopic and robotic surgeries are regarded as minimally invasive techniques, the main advantages of RARP, such as seven degrees of freedom in robotic arm movement and magnified 3D vision of the robotic platform, result in decreased postoperative complications.

Incontinence is another complication of prostatectomy that greatly affects quality of life [5]. The urinary incontinence rate is influenced by the definition of incontinence. Thus, as reported previously, any systematic review is difficult to accomplish owing to the varying definitions used for urinary incontinence, such as involuntary urine loss [6], needing zero or 1 pad [7] and also those in the International Consultation on Incontinence Questionnaire-Short Form survey [8].

The urinary incontinence rate after 12 months was significantly lower with RARP than with LRP in this meta-analysis and in other randomized controlled trials, in which the rates for RARP and LRP were 6% and 17%, respectively, but without statistical significance owing to the limited study population [9]. Many modifications have been suggested in the field of robotics to improve the continence rate. Patel et al. [10] reported a peri-urethral suspension suture technique to improve the rate (92.8% vs 83%; p=0.013 over 3 months). A modified posterior reconstruction that increased the continence rate by 4 weeks was reported by Coelho et al. [11]. In 2011, Asimakopoulos et al. [9] suggested a pubovesical-complex-sparing technique, in which a ventral plane was developed between the detrusor apron and the prostate. Owing to the technical feasibility of robotic assistance, reconstruction procedures have additionally improved the continence rate.

The potency recovery rate is another major concern for patients undergoing prostatectomy. The most common reason
### A Positive surgical margin

| Study or subgroup | RARP | LRP | Risk ratio | Risk ratio |
|-------------------|------|------|------------|------------|
|                   | Events | Total | Events | Total | Weight (%) | M-H, fixed, 95% CI | Year | M-H, fixed, 95% CI |
| **1.2.1 pT2 cases** | | | | | | | | |
| Rozell 2007       | 49 | 110 | 37 | 103 | 21.5 | 1.24 [0.89, 1.73] | 2007 | | |
| Drouin 2009       | 6 | 61 | 8 | 70 | 4.2 | 0.86 [0.32, 2.34] | 2009 | | |
| Magheli 2011      | 36 | 387 | 29 | 432 | 15.4 | 1.39 [0.87, 2.22] | 2011 | | |
| Asimakopoulos 2011| 3 | 43 | 4 | 52 | 2.0 | 0.91 [0.21, 3.83] | 2011 | | |
| Koutlidis 2012    | 18 | 149 | 8 | 79 | 5.9 | 1.19 [0.54, 2.62] | 2012 | | |
| Porpiglia 2013    | 5 | 37 | 6 | 37 | 3.4 | 0.83 [0.28, 2.49] | 2013 | | |
| Stolzenburg 2013  | 6 | 67 | 5 | 77 | 2.6 | 1.38 [0.44, 4.32] | 2013 | | |
| **Subtotal (95% CI)** | 854 | 850 | 55.1 | 1.22 [0.98, 1.54] | | | |
| Total events      | 123 | 97 | | | | | |
| Heterogeneity: $\chi^2$=1.43, df=6 (p=0.06); $I^2$=0% | | | | | | | |
| Test for overall effect: Z=1.62 (p=0.11) | | | | | | | |

| **1.2.2 pT3 cases** | | | | | | | | |
| Rozell 2007       | 3 | 23 | 5 | 30 | 2.4 | 0.78 [0.21, 2.94] | 2007 | | |
| Drouin 2009       | 6 | 10 | 8 | 15 | 3.6 | 1.13 [0.56, 2.25] | 2009 | | |
| Asimakopoulos 2011| 5 | 9 | 2 | 8 | 1.2 | 2.22 [0.58, 8.44] | 2011 | | |
| Magheli 2011      | 66 | 136 | 39 | 89 | 26.6 | 1.11 [0.83, 1.48] | 2011 | | |
| Koutlidis 2012    | 12 | 26 | 6 | 25 | 3.4 | 1.92 [0.85, 4.33] | 2012 | | |
| Stolzenburg 2013  | 13 | 33 | 6 | 20 | 4.2 | 1.31 [0.59, 2.90] | 2013 | | |
| Porpiglia 2013    | 11 | 22 | 6 | 22 | 3.4 | 1.83 [0.82, 4.08] | 2013 | | |
| **Subtotal (95% CI)** | 259 | 209 | 44.9 | 1.26 [1.00, 1.55] | | | |
| Total events      | 116 | 72 | | | | | |
| Heterogeneity: $\chi^2$=3.93, df=6 (p=0.69); $I^2$=0% | | | | | | | |
| Test for overall effect: Z=1.98 (p=0.05) | | | | | | | |

**Total (95% CI) 1,113 1,059 100.0 1.23 [1.05, 1.46] | | | | | |
| Total events 239 | 169 | | | | | |
| Heterogeneity: $\chi^2$=5.35, df=13 (p=0.07); $I^2$=0% | | | | | | |
| Test for overall effect: Z=2.49 (p=0.01) | | | | | | |

**Test for subgroup differences: Chi$^2$=0.04, df=1 (p=0.84); $I^2$=0% | | | | | |

### B Biochemical recurrence

| Study or subgroup | RARP | LRP | Risk ratio | Risk ratio |
|-------------------|------|------|------------|------------|
|                   | Events | Total | Events | Total | Weight (%) | M-H, fixed, 95% CI | Year | M-H, fixed, 95% CI |
| **1.1 PSA>0.2 ng/mL** | | | | | | | | |
| Drouin 2009       | 7 | 71 | 10 | 85 | 3.3 | 0.84 [0.34, 2.09] | 2009 | | |
| Asimakopoulos 2011| 4 | 52 | 2 | 60 | 0.7 | 2.31 [0.44, 12.09] | 2011 | | |
| Porpiglia 2013    | 1 | 50 | 4 | 53 | 1.4 | 0.27 [0.03, 2.29] | 2013 | | |
| Ploussard 2014    | 104 | 1,009 | 248 | 1,377 | 76.4 | 0.57 [0.46, 0.71] | 2014 | | |
| **Subtotal (95% CI)** | 1,182 | 1,575 | 81.8 | 0.59 [0.48, 0.73] | | | |
| Total events 116 | 264 | | | | | | |
| Heterogeneity: $\chi^2$=3.78, df=3 (p=0.09); $I^2$=21% | | | | | | | |
| Test for overall effect: Z=5.02 (p<0.00001) | | | | | | | |

| **1.2 PSA>0.2 ng/mL** | | | | | | | | |
| Stolzenburg 2013    | 9 | 100 | 6 | 100 | 2.2 | 1.50 [0.55, 4.06] | 2013 | | |
| **Subtotal (95% CI)** | 100 | 100 | 2.2 | 1.50 [0.55, 4.06] | | | |
| Total events 9 | 6 | | | | | | |
| Heterogeneity: Not applicable | | | | | | | |
| Test for overall effect: Z=0.90 (p=0.42) | | | | | | | |

| **1.3 PSA>0.4 ng/mL** | | | | | | | | |
| Lee 2009           | 0 | 21 | 3 | 31 | 1.0 | 0.21 [0.01, 3.83] | 2009 | | |
| **Subtotal (95% CI)** | 21 | 31 | 1.0 | 0.21 [0.01, 3.83] | | | |
| Total events 0 | 3 | | | | | | |
| Heterogeneity: Not applicable | | | | | | | |
| Test for overall effect: Z=1.06 (p=0.29) | | | | | | | |

| **1.4 not reported** | | | | | | | | |
| Cho 2009           | 9 | 60 | 26 | 60 | 9.5 | 0.35 [0.18, 0.68] | 2009 | | |
| Magheli 2011       | 28 | 522 | 15 | 522 | 5.5 | 1.87 [1.01, 3.45] | 2011 | | |
| **Subtotal (95% CI)** | 582 | 582 | 14.9 | 0.90 [0.59, 1.37] | | | |
| Total events 37 | 41 | | | | | | |
| Heterogeneity: $\chi^2$=13.26, df=1 (p=0.0003); $I^2$=92% | | | | | | | |
| Test for overall effect: Z=0.48 (p=0.63) | | | | | | | |

**Total (95% CI) 1,885 2,288 100.0 0.65 [0.55, 0.78] | | | | | |
| Total events 162 | 314 | | | | | | |
| Heterogeneity: $\chi^2$=22.59, df=7 (p=0.002); $I^2$=69% | | | | | | | |
| Test for overall effect: Z=4.64 (p=0.00001) | | | | | | | |

**Test for subgroup differences: Chi$^2$=6.46, df=3 (p=0.09); $I^2$=53.6% | | | | | | | |

---

**Fig. 4.** Cumulative analyses of robot-assisted radical prostatectomy comparing laparoscopic radical prostatectomy in oncologic outcome (A: Positive surgical margin, B: Biochemical recurrence). RARP, robot-assisted radical prostatectomy; LRP, laparoscopic radical prostatectomy; M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom.
for failure to reach pentafecta is erectile dysfunction (35%) [12]. Our findings differed from those previously reported by NETSCC (2012), which showed no difference in the potency rate between RARP and LRP at 12 months postoperatively. In our meta-analysis, the potency rate of RARP at 12 months was significantly higher than that for LRP. Different potency recovery rates could be due to several factors, including different definitions of erectile dysfunction, various characteristics of the surgery, and differences in postsurgical rehabilitation [13]. Potency recovery was measured by using several methods, including the IIEF-5 and the Sexual Health Inventory for Men score. Various techniques for preserving potency have been developed on the robotic platform, including cavernous nerve preservation. Several nerve-sparing techniques were developed in previous studies. For example, Ahlering et al. [4] evaluated the adverse effects of electrocautery on dissection of the prostate and the superiority of cautery-free nerve-sparing techniques on the recovery of potency. Menon et al. [14] evaluated the “Veil of Aphrodite” technique in which the inter-fascial plane

Fig. 5. Funnel plot of the studies of organ injury (A), blood transfusion rate (B), operative time (C), length of stay (D), potency (E) and overall biochemical recurrence (F) used in the meta-analysis.
Robot and laparoscopic radical prostatectomy was extended towards the apex and laterally towards the prostatic pedicle. At 6 to 18 months postoperatively, 94% of men who attempted sexual intercourse after undergoing this technique reported success, with a median SHIM score of 18 out of 25. Following recent discoveries of the periprostatic fascial anatomy, extrafascial, interfascial, and intrafascial approaches have been developed. Comparing interfascial and extrafascial approaches, Shikanov et al. [15] reported a significantly improved potency rate (p=0.03) using the interfascial approach.

Three-dimensional magnified visualization of the robotic platform has enabled meticulous dissection of the periprostatic fascia layer and the neurovascular bundle. Further insights into the multilayered structure of the periprostatic fascia and the course of the cavernous nerves have supported the development of intra- or interfascial surgical planes, which have enabled improved functional outcomes in urinary incontinence and potency. A PSA level >0.2 ng/mL was selected as the important criterion, based on recommendations of clinical practice guidelines [16]. In an oncological RARP study, Menon et al. [17] reported biochemical-free survival rates of 95.1%, 90.6%, 86.6%, and 81.0% after 1, 3, 5, and 7 years, respectively. Few studies have reported BCR rates after RARP and LRP. Recently, Porpiglia et al. [18] reported BCR-free survival rates of 98% for a RARP group and 92.5% for an LRP group (p=0.019).

The oncologic outcome in the current study was noteworthy because of the statistically significant differences in BCR rates between the two groups. Ficarra et al. [13] demonstrated that BCR was significantly influenced by surgical experience, clinical tumor size, and anatomic tumor characteristics. Kim et al. [19] analyzed the preoperative predictors of BCR using multivariable analysis, which suggested that PSA, pathologic stage, pathologic Gleason score, and PSM were independently associated with BCR. In a Japanese study, the predictive factors of BCR following RARP were serum PSA levels, the percentage of positive cores, and the Gleason score. PSA density was also a strong predictor of advanced pathological features and BCR [20]. In our systematic review, the oncologic results for BCR showed a statistically significantly improved BCR in the RARP group relative to the LRP group, although the propensity score matching was similar between the groups. The PSM patients in the intermediate- and high-risk disease groups had higher rates of BCR than did those who were marginal or negative. However, the PSM in the low-risk disease group was not associated with disease progression [21]. After adjustment for differences in clinical and pathological features, the presence of a base margin was significantly associated with a shorter time to recurrence for intermediate- and high-risk disease. The apex margin also was associated with the time to recurrence, but not statistically so for intermediate-risk disease. Thus, the similar PSM rate did not indicate a similar BCR rate. The length of the PSM was also independently predictive of BCR. Patients with a PSM <1 mm appeared to have similar outcomes compared with those with negative surgical margins [22]. Patients with a PSM <1 mm did not differ from those with a negative margin, and as the length of the positive margin increased so did the risk of BCR. Interestingly, the risk of BCR did not differ between patients with a negative surgical margin and those with a PSM <1 mm.

The current study had several limitations. First, because this is a relatively new procedure, data were lacking on long-term oncologic results following RARP, such as the cancer-specific survival rate. Second, significant heterogeneity was evident in terms of surgical experience and definition of functional outcomes. Third, some of recently published articles had far larger cohorts, which strongly influenced the meta-analysis. Fourth, there was an era bias in several centers in that RARP was performed after LRP.

CONCLUSIONS

In conclusion, RARP showed favorable results compared with LRP. However, few long-term, high-quality studies are available comparing RARP and LRP. Although further studies are needed, our results revealed that RARP had an improved BCR rate, potency rate, and continence rate with fewer complications than LRP. Further high-quality studies that minimize confounding and selection biases with long-term follow-up are needed to further clarify the clinical efficacy and safety of RARP.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGMENTS

This study was completed as part of the health technology assessment report (project No. NA 2013-007) funded by National Evidence-based Healthcare Collaborating Agency in South Korea.
REFERENCES

1. Berge V, Berg RE, Hoff JR, Wessel N, Diep LM, Karlsten SJ, et al. A prospective study of transition from laparoscopic to robot-assisted radical prostatectomy: quality of life outcomes after 36-month follow-up. Urology 2013;81:781-6.

2. Asimakopoulos AD, Miano R, Di Lorenzo N, Spera E, Vespasiani G, Mugnieri C. Laparoscopic versus robot-assisted bilateral nerve-sparing radical prostatectomy: comparison of pentafecta rates for a single surgeon. Surg Endosc 2013;27:4297-304.

3. Lee YS, Han WK, Oh YT, Choi YD, Yang SC, Rha KH. Robot-assisted laparoscopic radical prostatectomy: four cases. Yonsei Med J 2007;48:341-6.

4. Ahlering TE, Skarecky D, Borin J. Impact of cautery versus cautery-free preservation of neurovascular bundles on early return of potency. J Endourol 2006;20:586-9.

5. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroid L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61.

6. van der Poel HG, de Blok W, Joshi N, van Muilekom E. Preservation of lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy. Eur Urol 2009;55:892-900.

7. Borin JF, Skarecky DW, Narula N, Ahlering TE. Impact of urethral stump length on continence and positive surgical margins in robot-assisted laparoscopic prostatectomy. Urology 2007;70:173-7.

8. Novara G, Ficarra V, D’elia C, Secco S, Cioffi A, Cavalleri S, et al. Evaluating urinary continence and preoperative predictors of urinary continence after robot assisted laparoscopic radical prostatectomy. J Urol 2010;184:1028-33.

9. Asimakopoulos AD, Pereira Fraga CT, Annino F, Pasqualetti P, Calado AA, Mugnier C. Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy. J Sex Med 2011;8:1503-12.

10. Patel VR, Coelho RF, Palmer KJ, Rocco B. Periurethral suspension stitch during robot-assisted laparoscopic radical prostatectomy: description of the technique and continence outcomes. Eur Urol 2009;56:472-8.

11. Coelho RF, Chauhan S, Orvieto MA, Sivaraman A, Palmer KJ, Coughlin G, et al. Influence of modified posterior reconstruction of the rhabdosphincter on early recovery of continence and anastomotic leakage rates after robot-assisted radical prostatectomy. Eur Urol 2011;59:72-80.

12. Patel VR, Sivaraman A, Coelho RF, Chauhan S, Palmer KJ, Orvieto MA, et al. Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy. Eur Urol 2011;59:702-7.

13. Ficarra V, Novara G, Fracalanza S, D’Elia C, Secco S, Iafra M, et al. A prospective, non-randomized trial comparing robot-assisted laparoscopic and retropubic radical prostatectomy in one European institution. BJU Int 2009;104:534-9.

14. Menon M, Shrivastava A, Bhandari M, Satyanarayana R, Siva S, Agarwal PK. Vattikuti Institute prostatectomy: technical modifications in 2009. Eur Urol 2009;56:89-96.

15. Shikanov S, Woo J, Al-Ahmadie H, Katz MH, Zagaja GP, Shalhav AL, et al. Extravesical versus interfascial nerve-sparing technique for robotic-assisted laparoscopic prostatectomy: comparison of functional outcomes and positive surgical margins characteristics. Urology 2009;74:611-6.

16. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-79.

17. Menon M, Bhandari M, Gupta N, Lane Z, Peabody JO, Rogers CG, et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol 2010;58:838-46.

18. Porpiglia F, Morra I, Lucci Chiarissi M, Manfredi M, Mele F, Grande S, et al. Randomised controlled trial comparing laparoscopic and robot-assisted radical prostatectomy. Eur Urol 2013;63:606-14.

19. Kim KH, Lim SK, Shin TY, Chung BH, Hong SJ, Rha KH. Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years. Asian J Androl 2013;15:404-8.

20. Hashimoto T, Yoshioka K, Gondo T, Ozu C, Horiguchi Y, Namiki K, et al. Preoperative prognostic factors for biochemical recurrence after robot-assisted radical prostatectomy in Japan. Int J Clin Oncol 2014;19:702-7.

21. Choo MS, Cho SY, Ko K, Jeong CW, Lee SB, Ku JH, et al. Impact of positive surgical margins and their locations after radical prostatectomy: comparison of biochemical recurrence according to risk stratification and surgical modality. World J Urol 2014;32:1401-9.

22. Shikanov S, Song J, Royce C, Al-Ahmadie H, Zorn K, Steinberg G, et al. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol 2009;182:139-44.

23. Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG, et al. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol 2010;57:453-8.

24. Durand X, Vaessen C, Bitker MO, Richard F. Retropubic, laparoscopic and robot-assisted total prostatectomies: comparison of postoperative course and histological and functional results
based on a series of 86 prostatectomies. Prog Urol 2008;18:60-7.

25. Hakimi AA, Blitstein J, Feder M, Shapiro E, Ghavamian R. Direct comparison of surgical and functional outcomes of robotic-assisted versus pure laparoscopic radical prostatectomy: single-surgeon experience. Urology 2009;73:119-23.

26. Ball AJ, Gambill B, Fabrizio MD, Davis JW, Given RW, Lynch DF, et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. J Endourol 2006;20:723-31.

27. Drouin SJ, Vaessen C, Hupertan V, Comperat E, Misraï V, Haertig A, et al. Comparison of mid-term carcinologic control obtained after open, laparoscopic, and robot-assisted radical prostatectomy for localized prostate cancer. World J Urol 2009;27:599-605.

28. Gosseine PN, Mangin P, Leclers F, Cormier L. Pure laparoscopic versus robotic-assisted laparoscopic radical prostatectomy: comparative study to assess functional urinary outcomes. Prog Urol 2009;19:611-7.

29. Hu JC, Nelson RA, Wilson TG, Kawachi MH, Ramin SA, Lau C, et al. Perioperative complications of laparoscopic and robotic-assisted laparoscopic radical prostatectomy. J Urol 2006;175:541-6.

30. Joseph JV, Vicente I, Madeb R, Erturk E, Patel HR. Robot-assisted vs pure laparoscopic radical prostatectomy: are there any differences? BJU Int 2005;96:39-42.

31. Rozet F, Jaffe J, Braud G, Harmon J, Cathelineau X, Barret E, et al. A direct comparison of robotic assisted versus pure laparoscopic radical prostatectomy: a single institution experience. J Urol 2007;178:478-82.

32. Trabulsli EJ, Linden RA, Gomella LG, McGinnis DE, Strup SE, Lallas CD. The addition of robotic surgery to an established laparoscopic radical prostatectomy program: effect on positive surgical margins. Can J Urol 2008;15:3994-9.

33. Cho JW, Kim TH, Sung GT. Laparoscopic radical prostatectomy versus robot-assisted laparoscopic radical prostatectomy: a single surgeon’s experience. Korean J Urol 2009;50:1198-202.

34. Kasraein A, Barret E, Chan J, Sanchez-Salas R, Validire P, Cathelineau X, et al. Comparison of the rate, location and size of positive surgical margins after laparoscopic and robot-assisted laparoscopic radical prostatectomy. BJU Int 2011;108:1174-8.

35. Kermarrec I, Mangin P, Koutlidis N, Mourey E, Cormier L. Does robotics improve laparoscopic radical prostatectomy in complex surgical cases? Prog Urol 2010;20:638-43.

36. Koutlidis N, Mourey E, Champigneulle J, Mangin P, Cormier L. Robot-assisted or pure laparoscopic nerve-sparing radical prostatectomy: what is the optimal procedure for the surgical margins? A single center experience. Int J Urol 2012;19:1076-81.

37. Lee HW, Lee HM, Seo SI. Comparison of initial surgical outcomes between laparoscopic radical prostatectomy and robot-assisted laparoscopic radical prostatectomy performed by a single surgeon. Korean J Urol 2009;50:468-74.

38. Magheli A, Gonzalgo ML, Su LM, Guzzo TJ, Netto G, Humphreys EB, et al. Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. BJU Int 2011:107:1956-62.

39. Nakamura LY, Nunez RN, Castle EP, Andrews PE, Humphreys MR. Different approaches to an inguinal hernia repair during a simultaneous robot-assisted radical prostatectomy. J Endourol 2011;25:621-4.

40. Park B, Kim W, Jeong BC, Jeon SS, Lee HM, Choi HY, et al. Comparison of oncological and functional outcomes of pure versus robotic-assisted laparoscopic radical prostatectomy performed by a single surgeon. Scand J Urol 2013;47:10-8.

41. Ploussard G, de la Taille A, Moulin M, Vordos D, Hoznek A, Abbou CC, et al. Comparisons of the perioperative, functional, and oncologic outcomes after robot-assisted versus pure extraperitoneal laparoscopic radical prostatectomy. Eur Urol 2014;65:610-9.

42. Stolzenburg JU, Qazi HA, Holze S, Mende M, Nicolaus M, Franz T, et al. Evaluating the learning curve of experienced laparoscopic surgeons in robot-assisted radical prostatectomy. J Endourol 2013;27:80-5.

43. Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int 2012;109:898-905.

44. Wolanski P, Chabert C, Jones L, Mullavey T, Walsh S, Gianduzzi T. Preliminary results of robot-assisted laparoscopic radical prostatectomy (RALP) after fellowship training and experience in laparoscopic radical prostatectomy (LRP). BJU Int 2012;110 Suppl 4:64-70.